Abstract
Analogues of human growth hormone-releasing hormone-(1–30)-amide [GH-RH(1–30)- amide] were tested for their ability to stimulate GH release in vivo by injecting the peptides intravenously (iv), subcutaneously (sc), and intramuscularly (im). The analogues involved derivatization with Nle27 and Gaba substituents at the C-terminus with or without D-amino acid(s) in the peptide chain. The potency of the analogues was compared to that of GH-RH(1–29)-amid testing their ability to release GH at 5, 15 and 30 min after the administration. In iv test the potency of the analogues was 1.2–2 times higher than that of the GH-RH(1–29)- amide, and no significant differences were detected between the potencies of the analogues with or without D-amino acid. In the sc test the analogue with D-Ala2, Nle27, and Gaba30 substitutions expressed 8.0–51.7 times higher potency than the GH-RH(1–29)-amide, however, the analogue with similar modifications but with L-Ala2 showed the same low potency (1.2–2.1) as in the iv test. Results from the im experiments were similar to those of SC test. The most potent analogues were those which had D-Ala2, Nle27, and Gaba30 substitutions with Gly15 or Leu15. Circular dichroism (CD) spectra of the analogues showed that Leu in position 15 increased the stability of the predominant α-helix conformation, which improved the absorption of the molecule. The introduction of D-Arg11 into the D- Ala2, Leul5, Nle27 Gaba30 GH-RH(1–30)-amide molecule decreased the sc and im potencies, without altering the iv activities. Our data indicate that in vivo GH-releasing potency of the GH-RH(1–30)- amide analogues highly depends on the route of administration, and that D-amino acid(s) are responsible for the increased sc and im potency. Parenteral absorption of the analogue appears to be related to its α-helical conformation.
Similar content being viewed by others
References
Wehrenberg W.B., Ling N. In vivo biological potency of rat and human growth hormone-releasing factor and fragments of human growth hormone-releasing factor. Biochem. Biophys. Res. Commun. 115: 525, 1983.
Grossman A., Savage M.O., Lytras N., Preece M.A., Sueiras-Diaz J., Coy D.H., Rees L.H., Besser G.M. Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth hormone deficient children and young adults. Clin. Endocrinol. (Oxf.) 21: 321, 1984.
Barron J.L, Coy D.H., Millar R.P. Growth hormone responses to growth hormone-releasing hormone(1–29)NH2 and D-Ala2 analog in normal man. Peptides 6: 575, 1985.
Clark R.G., Robinson I.C.A.F. Growth induced by pulsatile infusion or an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature 314: 281, 1985.
Bokser L, Schally A.V. Delayed release formulation of the somatostatin analog RC-160 inhibits the growth hormone (GH) response to GH-releasing factor -(1–29)NH2 and decreases elevated prolactin levels in rats. Endocrinology 123: 1735, 1988.
Guillemin R., Zeytin F., Ling N., Bohlen P., Esch F., Brazeau P., Bloch B., Wehrenberg B. Growth hormone-releasing factor: Chemistry and physiology. Proc. Soc. Exp. Biol. Med. 175: 407, 1984.
Thorner M.O., Vance K.E., Evans W.S., Blizzard R.M., Rogol A.D., Ho K., Leong DA, Borges J.L.C., Crontin M.J., MacLeod R.M., Kovács K., Asa S., Horvát E., Frohman L, Furlanetto R., Klingesmith F.J., Brook C, Smith P., Reichlin S., Rivier J., Vale W. Physiological and clinical studies of GRF and GH. Rec. Prog. Horm. Res. 42: 589, 1986.
Rafferty B., Schulster D. Radioimmunoassay for human growth hormone-releasing factor (hGRFI-40): comparison of plasma immunoreactive GRF after intravenous and subcutaneous administration to rats. Mol. Cell. Endocrinol. 47: 19, 1985.
Rafferty B., Poole S., Clarke R., Schulster D. Growth hormone-releasing factor analogue (hGRF1-29NH2): Immunoreactive GRF plasma levels after intravenous and subcutaneous administration. J. Endocrinol. 107: R5, 1985.
Kovacs M., Gulyás J., Bajusz S., Schally A.V. An evaluation of intravenous, subcutaneous, and in vitro activity of new agmatine analogs of growth hormone-releasing hormone hGH-RH(1–29)NH2. Life Sci. 42::27, 1988.
Rafferty B., Coy D.H., Poole S. Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1–29)-amide. Peptides 9: 207, 1988.
Hodate K., Johke T., Ohashi S. Response of growth hormone release to human growth hormone-releasing factor and its analogs in the bovine. Endocrinol. Jpn. 33: 519, 1986.
Pelletier G., Petitclerk D., Lapierre H., Bernier-Cardou M., Morisset J., Gaudreau P., Couture V., Brazeau P. Injection of synthetic human growth hormone releasing factors in dairy cows. 1. Effect on feed intake and milk yield and composition. J. Dairy Sci. 70: 2511, 1987.
Coy D.H., Murphy W.A., Sueiras-Diaz J., Coy E.J., Lance V.A. Structure-activity studies on the N-terminal region of growth hormone releasing factor. J. Med. Chem. 28: 181, 1985.
Lapierre H., Pelletier G., Petitclerc D., Dubreuil P., Morisset J., Gaudreau P.Y., Couture Brazeau P. Effect of human growth hormone-releasing factor(1–29)-NH2 on growth hormone release and milk production in dairy cows. J. Dairy Sci. 71: 92, 1988.
Murphy W.A., Coy D.H. Potent long-acting alkylated analogs of growth hormone-releasing factor. Peptide Res. 1: 36, 1988.
Bokser L, Zarandi M., Schally A.V. Evaluation of in vivo biological activity of new agmatine analogs of growth hormone-releasing hormone. Life Sci. 46: 999, 1990.
Zarandi M., Csernus V., Bokser L, Bajusz S., Groot K., Schally A.V. Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine. Int. J. Pept. Prot. Res. 36: 499, 1990.
Provencher S.W., Glöckner J. Estimation of globular protein secondary structure from circular dichroism. Biochemistry 20: 33, 1981.
Pugsley L.I. The application of the principles of statistical analysis to the biological assay of hormones. Endocrinology 39:161, 1946.
Felix A.M., Heimer E.P., Wang Ch., Lambros T.J., Fournier A., Mowles T.F., Maines S., Campbell R.M., Wegrzynski B.B., Toome V., Fry D., Madison V.S. Synthesis, biological activity and conformational analysis of cyclic GRF analogs. Int. J. Peptide Prot. Res. 32: 441, 1988.
Velicelebi G., Patthi S., Kaiser E.T. Design and biological activity of analogs of growth hormone-releasing factor with potential amphophilic helical carboxyl termini. Proc. Natl. Acad. Sci. USA 83: 5397, 1986.
Coy D.H., Hocart S.J., Murphy W.A. Human growth hormone-releasing hormone analogues with much improved in vitro growth hormone-releasing potencies in rat pituitary cells. Eur. J. Pharmacol. 204: 179, 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kovàcs, M., Mezõ, I., Teplán, I. et al. New Gaba-containing analogues of human Growth Hormone Releasing Hormene (1–30)-amide: II. Detailed in vivo biological examinations. J Endocrinol Invest 16, 799–805 (1993). https://doi.org/10.1007/BF03348930
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348930